AngioDynamics, Inc. $ANGO is Bastion Asset Management Inc.’s 3rd Largest Position

Bastion Asset Management Inc. grew its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 46.5% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 959,043 shares of the medical instruments supplier’s stock after acquiring an additional 304,217 shares during the period. AngioDynamics accounts for 4.6% of Bastion Asset Management Inc.’s investment portfolio, making the stock its 3rd biggest holding. Bastion Asset Management Inc. owned 2.36% of AngioDynamics worth $9,810,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its position in AngioDynamics by 13.5% during the second quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 16,747 shares of the medical instruments supplier’s stock valued at $166,000 after purchasing an additional 1,989 shares during the last quarter. Cerity Partners LLC raised its stake in shares of AngioDynamics by 22.0% during the 1st quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier’s stock worth $121,000 after purchasing an additional 2,333 shares in the last quarter. Mackenzie Financial Corp raised its stake in shares of AngioDynamics by 20.5% during the 1st quarter. Mackenzie Financial Corp now owns 77,445 shares of the medical instruments supplier’s stock worth $727,000 after purchasing an additional 13,152 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of AngioDynamics during the 1st quarter valued at about $145,000. Finally, American Century Companies Inc. grew its stake in shares of AngioDynamics by 23.0% in the 1st quarter. American Century Companies Inc. now owns 83,591 shares of the medical instruments supplier’s stock valued at $785,000 after buying an additional 15,649 shares in the last quarter. 89.43% of the stock is owned by institutional investors and hedge funds.

AngioDynamics Trading Down 1.5%

Shares of AngioDynamics stock opened at $11.73 on Friday. The firm has a fifty day simple moving average of $11.25 and a 200-day simple moving average of $10.11. The stock has a market capitalization of $483.28 million, a price-to-earnings ratio of -15.04 and a beta of 0.74. AngioDynamics, Inc. has a 1-year low of $6.63 and a 1-year high of $13.50.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. The business had revenue of $75.71 million for the quarter, compared to analyst estimates of $72.69 million. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. AngioDynamics’s revenue was up 12.1% compared to the same quarter last year. During the same period last year, the business posted ($0.11) EPS. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. As a group, research analysts predict that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

Insider Buying and Selling

In other AngioDynamics news, CEO James C. Clemmer purchased 10,000 shares of the company’s stock in a transaction on Thursday, October 9th. The shares were bought at an average cost of $11.15 per share, with a total value of $111,500.00. Following the transaction, the chief executive officer directly owned 882,529 shares in the company, valued at approximately $9,840,198.35. This represents a 1.15% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Lawrence T. Weiss purchased 10,000 shares of the business’s stock in a transaction dated Tuesday, October 21st. The shares were acquired at an average price of $11.81 per share, with a total value of $118,100.00. Following the completion of the acquisition, the senior vice president owned 93,597 shares of the company’s stock, valued at approximately $1,105,380.57. The trade was a 11.96% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 20,890 shares of company stock worth $239,532 in the last ninety days. Insiders own 6.00% of the company’s stock.

Analysts Set New Price Targets

ANGO has been the topic of several recent research reports. Lake Street Capital began coverage on shares of AngioDynamics in a research report on Wednesday, July 16th. They set a “buy” rating and a $24.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of AngioDynamics in a report on Wednesday, July 16th. Canaccord Genuity Group upped their price objective on shares of AngioDynamics from $17.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, October 3rd. Finally, Wall Street Zen downgraded shares of AngioDynamics from a “buy” rating to a “hold” rating in a research report on Saturday, October 4th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.33.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.